Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD Rats

Endocrine Research

Volumn 34, Issue 4, 2009, Pages 130-141

  Lv, Qihuan ^a   Wang, Youmin ^a   Wang, Wenping ^a   Wang, Liping ^a   Zhou, Xiaohui ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

High Fat Diet; Metabolic Syndrome; Pioglitazone; Visfatin

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TRIACYLGLYCEROL;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SUBCUTANEOUS FAT;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; DIET, ATHEROGENIC; DIETARY FATS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MICE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

EID: 72949093531     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800903287061     Document Type: Article

References (30)

1. O'Rahilly S. Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. BMJ 1997; 314:955-959.
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
3. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106:286-288.
4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415-1428.
5. Zigman JM, Nakano Y, Coppari R, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 2005; 115:3564-3572.
6. Ross R, Freeman J, Hudson R, Janssen I. Abdominal obesity, muscle composition, and insulin resistance in premenopausal women. J Clin Endocrinol Metab 2002; 87:5044-5051.
7. Jin H, Jiang B, Tang J, et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008; 79:412-418.
8. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab 2005; 19:547-566.
9. Zahorska-Markiewicz B, Janowska J, Olszanecka-Glinianowicz M, Zurakowski A. Serum concentrations of TNF-alpha and soluble TNF-alpha receptors in obesity. Int J Obes 2000; 24:1392-1395.
10. Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Janowska J, Zurakowski A. Serum concentrations of nitric oxide, TNF-alpha and TNF soluble receptors in women with overweight and obesity. Metabolism 2004; 53:1268-1273.
11. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426-430. (Pubitemid 40139988)
12. Berndt J, Klöting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54:2911-2916.
13. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91:295-299.
14. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. Clin Endocrinol Metab 2006; 91:1578-1581.
15. Jian WX, Luo TH, Gu YY, et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med 2006; 23:967-973.
16. López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55:2871-2875.
17. Chen CC, Li TC, Li CI, et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007; 56:1216-1220.
18. Dogru T, Sonmez A, Tasci I, et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76:24-29.
19. Krzysik-Walker SM, Ocón-Grove OM, Maddineni SR, Hendricks GL 3rd, Ramachandran R. Is visfatin an adipokine or myokine? Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens. Endocrinology 2008; 149:1543-1550.
20. Jung HS, Youn BS, Cho YM, et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 2005; 54:314-320.
21. Van Wijk JP, de Koning EJ, Castro Cabezas M, Rabelink TJ. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Diabetes Care 2005; 28:844-849.
22. Choi KC, Ryu OH, Lee KW, et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005; 336:747-753.
23. Kralisch S, Klein J, Lossner U, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005; 185:R1-8.
24. Hammarstedt A, Pihlajamäki J, Rotter Sopasakis V, et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 2006; 91:1181-1184.
25. Erdem G, Dogru T, Tasci I, et al. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 82:214-218.
26. Fruhbeck G, Bome-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001; 280:E827-847.
27. Barac A, Campia U, Matuskey LA, Lu L, Panza JA. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension. Am J Cardiol 2008; 101:980-985.
28. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89:4312-4319.
29. Bodles AM, Banga A, Rasouli N, Ono F, Kern PA, Owens RJ. Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 2006; 291:E1100-1105.
30. Li L, Yang G, Shi S, Yang M, Liu H, Boden G. The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo. Cytokine 2009; 45:12-19.